将适配体与短干扰RNA偶联作为治疗手段。
Coupling Aptamers to Short Interfering RNAs as Therapeutics.
作者信息
Cerchia Laura, Esposito Carla Lucia, Camorani Simona, Catuogno Silvia, Franciscis Vittorio de
机构信息
Istituto per l'Endocrinologia e l'Oncologia Sperimentale del CNR "G. Salvatore", Via S. Pansini 5, 80131 Naples, Italy.
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università di Napoli "Federico II", Via S. Pansini 5, 80131 Naples, Italy.
出版信息
Pharmaceuticals (Basel). 2011 Oct 27;4(11):1434-1449. doi: 10.3390/ph4111434.
RNA-based approaches are among the most promising strategies aimed at developing safer and more effective therapeutics. RNA therapeutics include small non-coding miRNAs, small interfering RNA, RNA aptamers and more recently, small activating RNAs. However, major barriers exist to the use of RNAs as therapeutics such as resistance to nucleases present in biological fluids, poor chemical stability, need of specific cell targeted delivery and easy entry into the cell. Such issues have been addressed by several recent reports that show the possibility of introducing chemical modifications in small RNAs to stabilize the molecular conformation and increase by several fold their integrity, while still preserving the functional activity. Further, several aptamers have been developed as excellent candidates for the specific recognition of cell surface targets. In the last few years, by taking advantage of recent advances in the small RNA field, molecular bioconjugates have been designed that permit specific targeting and may act as cargoes for cell internalization of small RNAs acting on gene expression that will be discussed in this review.
基于RNA的方法是开发更安全、更有效治疗药物最具前景的策略之一。RNA治疗药物包括小的非编码miRNA、小干扰RNA、RNA适配体,以及最近出现的小激活RNA。然而,将RNA用作治疗药物存在一些主要障碍,如对生物流体中存在的核酸酶有抗性、化学稳定性差、需要特异性细胞靶向递送以及易于进入细胞。最近的几份报告解决了这些问题,这些报告表明在小RNA中引入化学修饰以稳定分子构象并将其完整性提高几倍的可能性,同时仍保留其功能活性。此外,已经开发出几种适配体作为细胞表面靶点特异性识别的优秀候选物。在过去几年中,利用小RNA领域的最新进展,设计了分子生物共轭物,其允许特异性靶向,并且可以作为作用于基因表达的小RNA细胞内化的载体,本文将对此进行讨论。